<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521870</url>
  </required_header>
  <id_info>
    <org_study_id>DV3-MEL-01</org_study_id>
    <secondary_id>Keynote 184</secondary_id>
    <secondary_id>SYNERGY-001</secondary_id>
    <nct_id>NCT02521870</nct_id>
  </id_info>
  <brief_title>A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety,&#xD;
      tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections&#xD;
      in combination with intravenous pembrolizumab in patients with metastatic melanoma or&#xD;
      recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).&#xD;
&#xD;
      This study will be conducted in 2 phases. Phase 1 evaluates SD-101 given in combination with&#xD;
      pembrolizumab in melanoma populations (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with&#xD;
      progressive disease) in up to 4 Dose Escalation cohorts to identify a recommended Phase 2&#xD;
      dose (RP2D) to be evaluated in up to 4 Dose Expansion cohorts in Phase 2. Phase 2 also&#xD;
      includes up to 4 Dose Expansion cohorts of patients with HNSCC (anti-PD-1/L1 naïve and&#xD;
      anti-PD-1/L1 experienced with progressive disease).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A strategic restructuring including the planned conclusion of clinical oncology development&#xD;
    programs and no further sponsoring of the development of SD-101.&#xD;
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation Only - Number of Participants With DLTs</measure>
    <time_frame>Day 1 through Day 29</time_frame>
    <description>Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group</measure>
    <time_frame>Day 1 through Day 743</time_frame>
    <description>Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group</measure>
    <time_frame>Day 1 through Day 743</time_frame>
    <description>Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group</measure>
    <time_frame>Day 1 through Day 743</time_frame>
    <description>Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group</measure>
    <time_frame>Day 1 through Day 743</time_frame>
    <description>Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group</measure>
    <time_frame>Day 1 through Day 743</time_frame>
    <description>Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Head Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101(1)</intervention_name>
    <description>SD-101 administered intratumorally at escalating doses (up to 11 doses).</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).</description>
    <arm_group_label>Dose Escalation Phase 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SD-101(2)</intervention_name>
    <description>Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).</description>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 1)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 2)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 3)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).</description>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 1)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 2)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 3)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SD-101(3)</intervention_name>
    <description>Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).</description>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 5)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 6)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 7)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 8)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).</description>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 5)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 6)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 7)</arm_group_label>
    <arm_group_label>Dose Expansion Phase 2 (Cohort 8)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        [Inclusion Criteria (Phase 1 and Phase 2)]&#xD;
&#xD;
          1. Willing and able to provide written informed consent for the trial&#xD;
&#xD;
          2. Aged 18 years and older&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1&#xD;
&#xD;
          4. Patient must have adequate organ function as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
               1. Hematological:&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥ 1,500 /mcL&#xD;
&#xD;
                    -  Platelet count ≥ 100,000 /mcL&#xD;
&#xD;
                    -  Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L&#xD;
&#xD;
               2. Renal:&#xD;
&#xD;
                    -  Serum creatinine ≤ 1.5 × upper limit of normal (ULN) OR&#xD;
&#xD;
                    -  Measured or calculated creatinine clearance (GFR can also be used in place&#xD;
                       of creatinine or CrCl) ≥ 60 mL/min for subject with creatinine levels &gt; 1.5&#xD;
                       × institutional ULN&#xD;
&#xD;
               3. Hepatic:&#xD;
&#xD;
                    -  Serum total bilirubin:&#xD;
&#xD;
                    -  ≤ 1.5 × ULN OR&#xD;
&#xD;
                    -  &lt; 3 × ULN for persons with Gilbert's syndrome OR&#xD;
&#xD;
                    -  Direct bilirubin ≤ ULN for patients with total bilirubin levels &gt; 1.5 × ULN&#xD;
&#xD;
                    -  Aspartate transaminase (AST) and alanine transaminase (ALT) (also known as&#xD;
                       serum glutamic oxaloacetic transaminase and serum glutamic pyruvic&#xD;
                       transaminase)&#xD;
&#xD;
                    -  ≤ 2.5 × ULN OR&#xD;
&#xD;
                    -  ≤ 5 × ULN for patients with liver metastases&#xD;
&#xD;
               4. Coagulation:&#xD;
&#xD;
                    -  International normalized ratio or prothrombin time (PT) ≤ 1.5 × ULN unless&#xD;
                       patient is receiving anticoagulant therapy, and as long as PT or partial&#xD;
                       thromboplastin time (PTT) is within therapeutic range of intended use of&#xD;
                       anticoagulants&#xD;
&#xD;
                    -  Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless patient is&#xD;
                       receiving anticoagulant therapy, and as long as PT or PTT is within&#xD;
                       therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          5. Have provided 2 tissue biopsy samples taken of the target lesion (Lesion A) as a&#xD;
             single biopsy split into 2 samples or 2 separate biopsies that meet the minimal sample&#xD;
             size requirement per the study laboratory manual. One sample is for determining PD-L1&#xD;
             expression level by immunohistochemistry and can be an archival sample of the&#xD;
             anticipated target lesion that has been collected within 3 months of screening. The&#xD;
             other sample is for RNA expression profiling and must be a fresh biopsy.&#xD;
&#xD;
          6. Life expectancy of at least 6 months&#xD;
&#xD;
          7. Female patients of childbearing potential, as defined in Section 5.2.1, must have a&#xD;
             negative urine or serum pregnancy test within 72 hours prior to taking the first dose&#xD;
             of trial treatment. If the urine test is positive or cannot be confirmed as negative&#xD;
             then a serum test is required which must be negative for the patient to enroll. Women&#xD;
             of childbearing potential (WOCBP) must be willing to use 2 medically acceptable&#xD;
             methods of contraceptive from Day 1 through 120 days after the last dose of trial&#xD;
             treatment. The 2 medically acceptable birth control methods can be either 2 barrier&#xD;
             methods or a barrier method plus a hormonal method to prevent pregnancy. The following&#xD;
             are considered adequate barrier methods of contraception: diaphragm, condom (by the&#xD;
             partner), copper intrauterine device, sponge, or spermicide as per local regulations&#xD;
             or guidelines. Appropriate hormonal contraceptives will include any registered and&#xD;
             marketed contraceptive agent that contains an estrogen and/or a progestational agent&#xD;
             (including oral, subcutaneous, intrauterine, or intramuscular agents).&#xD;
&#xD;
             Male patients of reproductive potential, as described in Section 5.2.1, must agree to&#xD;
             use an adequate method of contraception from Day 1 through 120 days after the last&#xD;
             dose of trial treatment.&#xD;
&#xD;
             Abstinence is acceptable if this is the usual lifestyle and preferred contraception&#xD;
             for the patient.&#xD;
&#xD;
             [Inclusion Criteria (Phase 1 only: Melanoma)]&#xD;
&#xD;
          8. Histologically or cytologically confirmed unresectable or metastatic (stage IV)&#xD;
             melanoma&#xD;
&#xD;
          9. For Phase 1 Escalation Cohorts 1-4, must have at least 1 lesion that qualifies as a&#xD;
             target lesion per RECIST v1.1 except for the minimum measurement of 10 mm in diameter&#xD;
             for superficial lesions, is easily accessible (palpable or can be visualized by&#xD;
             ultrasound), and is amenable to multiple intratumoral injections. If superficial, the&#xD;
             target lesion must be documented photographically.&#xD;
&#xD;
             [Inclusion Criteria (Phase 2 only: Melanoma)]&#xD;
&#xD;
         10. Histologically or cytologically confirmed recurrent or unresectable or metastatic&#xD;
             (stage IV) melanoma&#xD;
&#xD;
         11. Must have at least 2 lesions that qualify as a target lesion per RECIST v1.1, and 1 of&#xD;
             the qualifying lesions must be easily accessible (palpable or can be visualized by&#xD;
             ultrasound) and amenable to multiple intratumoral injections. The target lesion should&#xD;
             be of sufficient size such that the required tumor biopsies do not significantly&#xD;
             affect tumor assessment per RECIST v1.1. If superficial, the target lesion must&#xD;
             measure at least 10 mm in diameter, be measured by calipers, and be documented&#xD;
             photographically. Tumor lesions situated in a previously irradiated area, or in an&#xD;
             area subjected to other loco-regional therapy, are usually not considered measurable&#xD;
             unless there has been demonstrated progression in the lesion. Approval from the&#xD;
             Medical Monitor is required to inject a previously radiated lesion.&#xD;
&#xD;
         12. Expansion Cohort 2: Must have documented PD per RECIST v1.1 on a prior treatment&#xD;
             regimen containing an anti-PD-1/L1 drug (see Appendix 6 for definition of PD per&#xD;
             RECIST v1.1)&#xD;
&#xD;
         13. Expansion Cohort 8: Must have all of the following:&#xD;
&#xD;
               1. Received at least 2 doses of an anti-PD-1/L1 therapy&#xD;
&#xD;
               2. PD occurred within 3 months after last dose of anti-PD-1/L1 therapy&#xD;
&#xD;
               3. Documented PD per RECIST v.1.1, which has been confirmed by a second assessment&#xD;
                  at least 4 weeks from the date of the first documented PD, in the absence of&#xD;
                  rapid clinical progression&#xD;
&#xD;
             [Inclusion Criteria (Phase 2 only: HNSCC)]&#xD;
&#xD;
         14. Histologically or cytologically confirmed recurrent or metastatic HNSCC that could not&#xD;
             be treated with curative intent&#xD;
&#xD;
         15. Must have at least 1 lesion that qualifies as a target lesion per RECIST v1.1, and&#xD;
             which must be easily accessible (palpable or can be visualized by ultrasound) and&#xD;
             amenable to multiple intratumoral injections. The target lesion should be of&#xD;
             sufficient size such that the required tumor biopsies do not significantly affect&#xD;
             tumor assessment per RECIST v1.1. Tumor lesions situated in a previously irradiated&#xD;
             area, or in an area subjected to other loco-regional therapy, are usually not&#xD;
             considered measurable unless there has been demonstrated progression in the lesion.&#xD;
             Approval from the Medical Monitor is required to inject a previously radiated lesion.&#xD;
&#xD;
         16. Expansion Cohort 4: Must have documented confirmed PD per RECIST v1.1 on a prior&#xD;
             treatment regimen containing an anti-PD-1/L1 drug (see Appendix 6 for definition of PD&#xD;
             per RECIST v1.1)&#xD;
&#xD;
         17. Expansion Cohort 7: Must have all of the following:&#xD;
&#xD;
               1. Received at least 2 doses of an anti-PD-1/L1 therapy, where the last dose of&#xD;
                  anti-PD-1/L1 therapy was within 6 months of study enrollment (Day 1)&#xD;
&#xD;
               2. Refractory response, ie, PD occurred within 3 months duration of the start of&#xD;
                  treatment on anti-PD-1/L1 therapy; OR resistant response, ie, PD occurred beyond&#xD;
                  3 months duration of treatment on anti-PD-1/L1 therapy and within 6 months after&#xD;
                  the last dose of treatment on anti-PD-1/L1 therapy&#xD;
&#xD;
               3. Documented PD per RECIST v.1.1, which has been confirmed by a second assessment&#xD;
                  at least 4 weeks from the date of the first documented PD, in the absence of&#xD;
                  rapid clinical progression&#xD;
&#xD;
        [Exclusion Criteria (Phase 1 and Phase 2)]&#xD;
&#xD;
          1. Received systemic chemotherapy or biological cancer therapy (except anti-PD-1/L1&#xD;
             therapy) within 3 weeks prior to study enrollment&#xD;
&#xD;
          2. Received prior radiotherapy within 2 weeks of start of study therapy. A shorter&#xD;
             washout period may be permitted after approval by the Medical Monitor.&#xD;
&#xD;
          3. Received small molecule inhibitor targeted therapy, such as tyrosine kinase&#xD;
             inhibitors, within 2 weeks prior to study enrollment&#xD;
&#xD;
          4. Has not recovered to CTCAE Grade 1 or better from the AEs due to cancer therapeutics&#xD;
             prior to study enrollment&#xD;
&#xD;
             NOTE: Patients with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia or Grade 2 AEs that&#xD;
             qualify as Grade 2 due to replacement hormonal or steroid therapy are exceptions to&#xD;
             this criterion and may qualify for the study with approval by a Dynavax Medical&#xD;
             Monitor.&#xD;
&#xD;
             If a patient received major surgery, they must have recovered adequately from the&#xD;
             toxicity and/or complications from the intervention prior to enrollment.&#xD;
&#xD;
          5. Received a transfusion of blood products (including platelets or red blood cells) or&#xD;
             colony-stimulating factors (including G-CSF, GM-CSF or recombinant erythropoietin)&#xD;
             within 4 weeks prior to study enrollment&#xD;
&#xD;
          6. Is expected to require any other form of anti-cancer therapy while in the trial&#xD;
&#xD;
          7. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy (including immune modulators or systemic&#xD;
             corticosteroids) within 7 days prior to study enrollment&#xD;
&#xD;
          8. Positive for active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xD;
             infection as determined by laboratory tests for HBsAg, anti-HBc, and anti-HBs;&#xD;
             anti-HCV; and anti-HIV -1/2, respectively&#xD;
&#xD;
          9. History of or current uveal or ocular or mucosal melanoma&#xD;
&#xD;
         10. Active infection including cytomegalovirus&#xD;
&#xD;
         11. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial through 120 days after the last dose of trial&#xD;
             treatment&#xD;
&#xD;
         12. Active autoimmune disease requiring systemic treatment in the past 2 years or a&#xD;
             disease that requires immunosuppressive medication including systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or&#xD;
             autoimmune thrombocytopenia. Replacement therapy (eg, thyroxine, insulin, or&#xD;
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)&#xD;
             is not considered a form of systemic treatment.&#xD;
&#xD;
         13. Current pneumonitis or history of (non-infectious) pneumonitis that required steroids&#xD;
&#xD;
         14. An immune-related AE from a previous immunotherapeutic agent that has not resolved to&#xD;
             Grade 1 or less prior to study enrollment. The exception is a Grade 2 AE which&#xD;
             qualifies as Grade 2 due to replacement steroid therapy which may be allowed with&#xD;
             approval by a Dynavax Medical Monitor.&#xD;
&#xD;
         15. Known active central nervous system metastases or carcinomatous meningitis&#xD;
&#xD;
             NOTE: Patients with previously treated brain metastases may participate provided they&#xD;
             are stable (without evidence of progression by imaging [using the identical imaging&#xD;
             modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the&#xD;
             first dose of trial treatment and with any neurologic symptoms returned to baseline),&#xD;
             have no evidence of new or enlarging brain metastases, and are not using steroids for&#xD;
             at least 7 days prior to trial treatment. This exception does not include&#xD;
             carcinomatous meningitis which is excluded regardless of clinical stability.&#xD;
&#xD;
         16. Use of any investigational agent within the last 28 days prior to study enrollment&#xD;
&#xD;
         17. Has received a live-virus vaccination within 30 days of planned treatment start.&#xD;
             Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
&#xD;
         18. Any other significant medical or psychiatric condition, laboratory abnormality, or&#xD;
             difficulty complying with protocol requirements that may increase the risk associated&#xD;
             with trial participation or trial drug administration that may interfere with the&#xD;
             interpretation of trial results and, in the judgment of the investigator, would make&#xD;
             the patient inappropriate for this trial&#xD;
&#xD;
         19. History of sensitivity to any component of SD-101 or hypersensitivity reaction to&#xD;
             treatment with a monoclonal antibody and/or any of its excipients&#xD;
&#xD;
         20. Any known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions are cutaneous melanoma or HNSCC under study per protocol, or basal cell&#xD;
             carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer&#xD;
             that has undergone potentially curative therapy.&#xD;
&#xD;
             [Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 1 and 5 only)]&#xD;
&#xD;
         21. Melanoma considered resectable with curative intent&#xD;
&#xD;
         22. Prior therapy with an anti-PD-1/L1 agent&#xD;
&#xD;
         23. Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients&#xD;
&#xD;
             [Exclusion Criteria (Phase 2, Melanoma Expansion Cohorts 2 and 8 only)]&#xD;
&#xD;
         24. Melanoma considered resectable with curative intent&#xD;
&#xD;
         25. Any prior combination therapy involving agents given by intratumoral injection that&#xD;
             target the innate immune pathway or system such as oncolytic viral or microbial&#xD;
             therapy (eg, T-VEC [talimogene laherparepvec]), toll-like receptors (TLR) agonists,&#xD;
             STING or RIG-1 and an anti-PD-1/L1 inhibitor&#xD;
&#xD;
             [Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 3 and 6 only)]&#xD;
&#xD;
         26. HNSCC considered resectable with curative intent&#xD;
&#xD;
         27. Prior therapy with an anti-PD-1/L1 agent&#xD;
&#xD;
         28. Require anticoagulation therapy&#xD;
&#xD;
             [Exclusion Criteria (Phase 2, HNSCC Expansion Cohorts 4 and 7 only)]&#xD;
&#xD;
         29. HNSCC considered resectable with curative intent&#xD;
&#xD;
         30. Any prior combination therapy involving agents given by intratumoral injection that&#xD;
             target the innate immune pathway or system such as oncolytic viral or microbial&#xD;
             therapy (eg, T-VEC), TLR agonists, STING or RIG-1 and an anti-PD-1/L1 inhibitor&#xD;
&#xD;
         31. Require treatment on anticoagulation therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Ribas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA School of Medicine (Melanoma)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Moores Cancer Center (HNSCC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Tüting, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center - Northside Hospital Central Research Department</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Healthcare</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center - Seidman Cancer center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care - Huntsman Cancer institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute</name>
      <address>
        <city>Wollstonecraft</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre - Ashford Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollywood Private Hospital / Affinity Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum BuxtehudeDermato-Onkologie Studienzentrale</name>
      <address>
        <city>Buxtehude</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Dresden Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Universitätsklinik Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>4710</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>July 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2021</results_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin Cancer</keyword>
  <keyword>Skin Tumors</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Cancer Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared under guidance of the New Rule - FDAAA 801 eff. Jan 2017. 3/2017 - additional changes forthcoming.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02521870/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02521870/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SD-101 1 mg</title>
          <description>Dose Escalation Cohort 4: Participants were administered SD-101 1 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P2">
          <title>SD-101 2 mg</title>
          <description>Dose Escalation Cohort 1: Participants were administered SD-101 2 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P3">
          <title>SD-101 4 mg</title>
          <description>Dose Escalation Cohort 2: Participants were administered SD-101 4 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P4">
          <title>SD-101 8 mg</title>
          <description>Dose Escalation Cohort 3: Participants were administered SD-101 8 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P5">
          <title>SD-101 8 mg in Anti-PD-1/L1-Naïve Melanoma</title>
          <description>Dose Expansion Cohort 1: Participants with melanoma who are anti-PD-1/L1-naïve were administered SD-101 8 mg intratumorally starting on Day 22 dose Q1W for 4 weeks followed by dose Q3W for 7 doses, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 doses (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P6">
          <title>SD-101 8 mg in Anti-PD-1/L1-Experienced Melanoma</title>
          <description>Dose Expansion Cohort 2: Participants with melanoma who are anti-PD-1/L1-experienced were administered SD-101 8 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 7 doses, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 doses (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P7">
          <title>SD-101 8 mg in Anti-PD-1/L1-Naïve HNSCC</title>
          <description>Dose Expansion Cohort 3: Participants with HNSCC who are anti-PD-1/L1-naïve were administered SD-101 8 mg intratumorally starting on Day 22 dose Q1W for 4 weeks followed by dose Q3W for 7 doses, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 doses (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P8">
          <title>SD-101 8 mg in Anti-PD-1/L1-Experienced HNSCC</title>
          <description>Dose Expansion Cohort 4: Participants with HNSCC who are anti-PD-1/L1-experienced were administered SD-101 8 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 7 doses, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 doses (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P9">
          <title>SD-101 2 mg in Anti-PD-1/L1-Naïve Melanoma</title>
          <description>Dose Expansion Cohort 5: Participants with melanoma who are anti-PD-1/L1-naïve were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 doses (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P10">
          <title>SD-101 2 mg in Anti-PD-1/L1-Naïve HNSCC</title>
          <description>Dose Expansion Cohort 6: Participants with HNSCC who are anti-PD-1/L1-naïve were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 doses (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P11">
          <title>SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCC</title>
          <description>Dose Expansion Cohort 7: Participants with HNSCC who are anti-PD-1/L1 refractory or resistant were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 doses (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
        <group group_id="P12">
          <title>SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma</title>
          <description>Dose Expansion Cohort 8: Participants with melanoma who are anti-PD-1/L1 refractory or resistant were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 doses (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1: Dose Escalation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed SD-101 Treatment (up to 11 Doses)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2: Dose Expansion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="24"/>
                <participants group_id="P10" count="28"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed SD-101 Treatment (up to 11 Doses)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="9"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed SD-101 Treatment Cycle 2 (up to 22 Doses)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2">4 participants completed pembrolizumab treatment (up to 35 cycles).</participants>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="22"/>
                <participants group_id="P10" count="28"/>
                <participants group_id="P11" count="23"/>
                <participants group_id="P12" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="17"/>
                <participants group_id="P11" count="17"/>
                <participants group_id="P12" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population comprises all participants who received at least one dose of SD-101. Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101, as specified by the statistical analysis plan. Participants who received 1 mg or 4 mg of SD-101 in Phase 1: Dose Escalation of the study are not included in the analysis groups.</population>
      <group_list>
        <group group_id="B1">
          <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
        </group>
        <group group_id="B2">
          <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
        </group>
        <group group_id="B3">
          <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
        </group>
        <group group_id="B4">
          <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
        </group>
        <group group_id="B5">
          <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
        </group>
        <group group_id="B6">
          <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
        </group>
        <group group_id="B7">
          <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
        </group>
        <group group_id="B8">
          <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
          <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="28"/>
            <count group_id="B6" value="23"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="9"/>
            <count group_id="B9" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="13.34"/>
                    <measurement group_id="B2" value="65.3" spread="12.44"/>
                    <measurement group_id="B3" value="65.6" spread="12.99"/>
                    <measurement group_id="B4" value="62.4" spread="15.25"/>
                    <measurement group_id="B5" value="62.6" spread="10.66"/>
                    <measurement group_id="B6" value="67.2" spread="9.59"/>
                    <measurement group_id="B7" value="61.0" spread="12.94"/>
                    <measurement group_id="B8" value="65.2" spread="12.35"/>
                    <measurement group_id="B9" value="64.4" spread="12.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Status</title>
          <description>ECOG PS = Eastern Cooperative Oncology Group Performance Status; 0 = Fully active, able to carry on all pre-disease performance without restriction (better outcome)&#xD;
1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work (worse outcome)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDL1 Expression</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 Dose Escalation Only - Number of Participants With DLTs</title>
        <description>Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.</description>
        <time_frame>Day 1 through Day 29</time_frame>
        <population>The safety population is defined as comprising of participants who received at least 1 dose of SD-101.</population>
        <group_list>
          <group group_id="O1">
            <title>SD-101 1 mg</title>
            <description>Dose Escalation Cohort 4: Participants were administered SD-101 1 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O2">
            <title>SD-101 2 mg</title>
            <description>Dose Escalation Cohort 1: Participants were administered SD-101 2 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O3">
            <title>SD-101 4 mg</title>
            <description>Dose Escalation Cohort 2: Participants were administered SD-101 4 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O4">
            <title>SD-101 8 mg</title>
            <description>Dose Escalation Cohort 3: Participants were administered SD-101 8 mg intratumorally as 4 weekly doses followed by 1 dose Q3W for 7 additional doses. Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O5">
            <title>SD-101 8 mg in Anti-PD-1/L1-Naïve Melanoma</title>
            <description>Dose Expansion Cohort 1: Participants with melanoma who are anti-PD-1/L1-naïve were administered SD-101 8 mg intratumorally starting on Day 22 dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O6">
            <title>SD-101 8 mg in Anti-PD-1/L1-Experienced Melanoma</title>
            <description>Dose Expansion Cohort 2: Participants with melanoma who are anti-PD-1/L1-experienced were administered SD-101 8 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O7">
            <title>SD-101 8 mg in Anti-PD-1/L1-Naïve HNSCC</title>
            <description>Dose Expansion Cohort 3: Participants with HNSCC who are anti-PD-1/L1-naïve were administered SD-101 8 mg intratumorally starting on Day 22 dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O8">
            <title>SD-101 8 mg in Anti-PD-1/L1-Experienced HNSCC</title>
            <description>Dose Expansion Cohort 4: Participants with HNSCC who are anti-PD-1/L1-experienced were administered SD-101 8 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O9">
            <title>SD-101 2 mg in Anti-PD-1/L1-Naïve Melanoma</title>
            <description>Dose Expansion Cohort 5: Participants with melanoma who are anti-PD-1/L1-naïve were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 weeks (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O10">
            <title>SD-101 2 mg in Anti-PD-1/L1-Naïve HNSCC</title>
            <description>Dose Expansion Cohort 6: Participants with HNSCC who are anti-PD-1/L1-naïve were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 weeks (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O11">
            <title>SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant HNSCC</title>
            <description>Dose Expansion Cohort 7: Participants with HNSCC who are anti-PD-1/L1 refractory or resistant were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 weeks (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
          <group group_id="O12">
            <title>SD-101 2 mg in Anti-PD-1/L1 Refractory or Resistant Melanoma</title>
            <description>Dose Expansion Cohort 8: Participants with melanoma who are anti-PD-1/L1 refractory or resistant were administered SD-101 2 mg intratumorally starting on Day 1 dose Q1W for 4 weeks followed by dose Q3W for 16 weeks (up to 20 total doses). Participants were also administered Pembrolizumab 200 mg intravenously Q3W starting on Day 1 for up to 35 treatments or until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation Only - Number of Participants With DLTs</title>
          <description>Dose-limiting toxicities (DLTs) are defined per protocol as specific AEs occurring from the time of the first injection (Day 1) through Day 29.</description>
          <population>The safety population is defined as comprising of participants who received at least 1 dose of SD-101.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group</title>
        <description>Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
        <time_frame>Day 1 through Day 743</time_frame>
        <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
          </group>
          <group group_id="O2">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
          </group>
          <group group_id="O4">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
          </group>
          <group group_id="O6">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
          </group>
          <group group_id="O7">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
          </group>
          <group group_id="O8">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Overall Response Rate (ORR) by Analysis Group</title>
          <description>Overall response rate (ORR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
          <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group</title>
        <description>Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
        <time_frame>Day 1 through Day 743</time_frame>
        <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study. This subset of participants analyzed comprises of participants with objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
          </group>
          <group group_id="O2">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
          </group>
          <group group_id="O4">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
          </group>
          <group group_id="O6">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
          </group>
          <group group_id="O7">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
          </group>
          <group group_id="O8">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Time to Objective Response by Analysis Group</title>
          <description>Time to objective response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
          <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study. This subset of participants analyzed comprises of participants with objective response.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.6"/>
                    <measurement group_id="O2" value="4.1" spread="2.96"/>
                    <measurement group_id="O3" value="5.1" spread="3.06"/>
                    <measurement group_id="O4" value="4.3" spread="2.98"/>
                    <measurement group_id="O5" value="2.3" spread=".92"/>
                    <measurement group_id="O6" value="2.4" spread="0.87"/>
                    <measurement group_id="O7" value="2.7" spread="1.09"/>
                    <measurement group_id="O8" value="2.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group</title>
        <description>Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
        <time_frame>Day 1 through Day 743</time_frame>
        <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study. This subset of participants analyzed comprises of participants with objective response.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
          </group>
          <group group_id="O2">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
          </group>
          <group group_id="O4">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
          </group>
          <group group_id="O6">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
          </group>
          <group group_id="O7">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
          </group>
          <group group_id="O8">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Duration of Response by Analysis Group</title>
          <description>Duration of response by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
          <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study. This subset of participants analyzed comprises of participants with objective response.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="6.42"/>
                    <measurement group_id="O2" value="11.7" spread="5.96"/>
                    <measurement group_id="O3" value="4.6" spread="6.57"/>
                    <measurement group_id="O4" value="7.6" spread="7.28"/>
                    <measurement group_id="O5" value="5.9" spread="4.93"/>
                    <measurement group_id="O6" value="6.3" spread="3.96"/>
                    <measurement group_id="O7" value="2.1" spread="0.07"/>
                    <measurement group_id="O8" value="8.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group</title>
        <description>Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
        <time_frame>Day 1 through Day 743</time_frame>
        <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
          </group>
          <group group_id="O2">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
          </group>
          <group group_id="O4">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
          </group>
          <group group_id="O6">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
          </group>
          <group group_id="O7">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
          </group>
          <group group_id="O8">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Disease Control Rate (DCR) by Analysis Group</title>
          <description>Disease Control Rate (DCR) by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
          <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group</title>
        <description>Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
        <time_frame>Day 1 through Day 743</time_frame>
        <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 1 and Cohort 5.</description>
          </group>
          <group group_id="O2">
            <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 2 and Cohort 8.</description>
          </group>
          <group group_id="O4">
            <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
          </group>
          <group group_id="O5">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3 and Cohort 6.</description>
          </group>
          <group group_id="O6">
            <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
          </group>
          <group group_id="O7">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4 and Cohort 7.</description>
          </group>
          <group group_id="O8">
            <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
            <description>Phase 1 Dose Escalation cohorts and Phase 2 Dose Expansion cohorts were rearranged as analysis groups for analyses to assess study objectives, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 Dose Escalation and Phase 2 Dose Expansion - Progression-Free Survival Rate by Analysis Group</title>
          <description>Progression-Free Survival (PFS) rate by analysis group based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was evaluated from Baseline (Day 1) through Day 743 or End of Study (EOS).</description>
          <population>The intent-to-treat (ITT) population comprises of all participants who were enrolled in the study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="70.9" upper_limit="93.3"/>
                    <measurement group_id="O2" value="71.9" lower_limit="54" upper_limit="83.8"/>
                    <measurement group_id="O3" value="46.7" lower_limit="28.4" upper_limit="63"/>
                    <measurement group_id="O4" value="48" lower_limit="27.8" upper_limit="65.6"/>
                    <measurement group_id="O5" value="46.4" lower_limit="26.6" upper_limit="64.1"/>
                    <measurement group_id="O6" value="43.5" lower_limit="23.3" upper_limit="62.1"/>
                    <measurement group_id="O7" value="31.6" lower_limit="12.9" upper_limit="52.2"/>
                    <measurement group_id="O8" value="37.5" lower_limit="8.7" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" lower_limit="62.6" upper_limit="88.1"/>
                    <measurement group_id="O2" value="63.3" lower_limit="45.2" upper_limit="76.8"/>
                    <measurement group_id="O3" value="33" lower_limit="17.2" upper_limit="49.8"/>
                    <measurement group_id="O4" value="24" lower_limit="9.8" upper_limit="41.7"/>
                    <measurement group_id="O5" value="26.5" lower_limit="10.5" upper_limit="45.7"/>
                    <measurement group_id="O6" value="17.4" lower_limit="5.4" upper_limit="35"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="25" lower_limit="3.7" upper_limit="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="54.3" upper_limit="82.3"/>
                    <measurement group_id="O2" value="60.4" lower_limit="42.4" upper_limit="74.4"/>
                    <measurement group_id="O3" value="21.4" lower_limit="8.6" upper_limit="37.9"/>
                    <measurement group_id="O4" value="14.4" lower_limit="3.9" upper_limit="31.4"/>
                    <measurement group_id="O5" value="21.2" lower_limit="7.1" upper_limit="40.3"/>
                    <measurement group_id="O6" value="17.4" lower_limit="5.4" upper_limit="35"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="12.5" lower_limit="0.7" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="54.3" upper_limit="82.3"/>
                    <measurement group_id="O2" value="53.7" lower_limit="35.7" upper_limit="68.7"/>
                    <measurement group_id="O3" value="21.4" lower_limit="8.6" upper_limit="37.9"/>
                    <measurement group_id="O4" value="9.6" lower_limit="1.7" upper_limit="25.7"/>
                    <measurement group_id="O5" value="15.9" lower_limit="4.2" upper_limit="34.4"/>
                    <measurement group_id="O6" value="8.7" lower_limit="1.5" upper_limit="24.2"/>
                    <measurement group_id="O7" value="00" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" lower_limit="48.2" upper_limit="77.8"/>
                    <measurement group_id="O2" value="49.9" lower_limit="31.9" upper_limit="65.5"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="9.6" lower_limit="1.7" upper_limit="25.7"/>
                    <measurement group_id="O5" value="15.9" lower_limit="4.2" upper_limit="34.4"/>
                    <measurement group_id="O6" value="4.3" lower_limit="0.3" upper_limit="18.2"/>
                    <measurement group_id="O7" value="00" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="44" upper_limit="75"/>
                    <measurement group_id="O2" value="40.3" lower_limit="22.3" upper_limit="57.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="9.6" lower_limit="1.7" upper_limit="25.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="44" upper_limit="75"/>
                    <measurement group_id="O2" value="40.3" lower_limit="22.3" upper_limit="57.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O7" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent through Day 743</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Melanoma Anti-PD-1/L1 Naïve SD-101 2 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 5.</description>
        </group>
        <group group_id="E2">
          <title>Melanoma Anti-PD-1/L1 Naïve SD-101 8 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 1.</description>
        </group>
        <group group_id="E3">
          <title>Melanoma Anti-PD-1/L1 Experienced SD-101 2 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 1 (SD-101 2 mg) and participants in Phase 2 Dose Expansion Cohort 8.</description>
        </group>
        <group group_id="E4">
          <title>Melanoma Anti-PD-1/L1 Experienced SD-101 8 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 1 Dose Escalation Cohort 3 (SD-101 8 mg) and participants in Phase 2 Dose Expansion Cohort 2.</description>
        </group>
        <group group_id="E5">
          <title>HNSCC Anti-PD-1/L1 Naïve SD-101 2 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 6.</description>
        </group>
        <group group_id="E6">
          <title>HNSCC Anti-PD-1/L1 Naïve SD-101 8 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 3.</description>
        </group>
        <group group_id="E7">
          <title>HNSCC Anti-PD-1/L1 Experienced SD-101 2 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion and Cohort 7.</description>
        </group>
        <group group_id="E8">
          <title>HNSCC Anti-PD-1/L1 Experienced SD-101 8 mg</title>
          <description>Some of the Phase 1 dose escalation cohorts and the 8 Phase 2 dose expansion cohorts were rearranged as analysis groups for analyses to assess the Phase 2 objectives as specified by the statistical analysis plan, based on tumor indications, anti-PD-1/L1 experience, and dose of SD-101. Results for Phase 2 objectives, using combined Phases 1 and 2 data, are presented by 2mg/lesion and 8mg/lesion doses.&#xD;
The participants in this analysis group include participants in Phase 2 Dose Expansion Cohort 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18_1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Autoimmune myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Infected neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Violence-related symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18_1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The sponsor terminated the trial early due to strategic restructuring, including the planned conclusion of clinical oncology development programs and no further sponsoring of the development of SD-101.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Janssen MD \ VP &amp; Chief Medical Officer</name_or_title>
      <organization>Dynavax Technologies, Inc.</organization>
      <phone>510-665-0414</phone>
      <email>rjanssen@dynavax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

